For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised Tuesday to examine lowering their prices in the United States, after ...

格隆汇9月25日｜丹麦制药巨头 诺和诺德 ( 125.44, 1.74, 1.41%) CEO Lars Jorgensen在美国国会参议院接受了质询，参议员认为，诺和诺德旗下减肥药物Wegovy和糖尿病药物Ozempic在美国的定价过高，明显高于它们在欧洲地区的售价。参议院卫生、教育、劳工和养老金委员会主席桑德斯援引数据称，诺和诺德今年已通过Wegovy和Ozempic获得了近500亿美元的收入 ...

Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But ...

Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

The CEO of Novo Nordisk took questions for more than two hours during a Senate Health Committee hearing focused on addressing ...

GLP-1 weight-loss drugs alleviate obesity as well as provide other health benefits. Yet they are also the focus of ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.